dupilumab

targets

all catalysts(33)

News(10)

• Pharma’s $500B patent problem will come in waves — not as a cliff
  Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.
  biopharma_dive · 6d ago
• Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
  Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.
  biopharma_dive · 6d ago
• Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
  New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this…
  biospace · 11d ago
• The top biopharma conferences in 2027
  Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch for in 2027.
  biopharma_dive · 12d ago
• Lilly, Foghorn part ways; Wave’s FDA-approved plans
  The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
  biopharma_dive · 17d ago
• Sanofi, Regeneron broaden alliance to find their next Dupixent
  The deal carries a $1 billion upfront payment and tasks the two companies to develop long-acting antibody drugs that go after the same targets as their blockbuster anti-inflammation agent.
  biopharma_dive · 17d ago
• Pfizer’s eczema drug clears skin in mid-stage trial
  Detailed results are competitive with Dupixent and Ebglyss, but the drug lacks differentiation amid an increasingly competitive landscape, one analyst argued.
  biopharma_dive · 17d ago
• Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor
  Sanofi and Regeneron have had a long and “sometimes contentious” partnership, BMO Capital Markets noted, as the companies contend with the looming loss of exclusivity of their blockbuster drug Dupi…
  biospace · 17d ago
• Sanofi builds on immunology alliance with Regeneron for $1B upfront
  As the patent cliff for Dupixent draws closer, Sanofi is turning back to the partnership that built the megablockbuster. The French pharma will pay $1 billion upfront to expand its antibody collabo…
  endpoints · 17d ago
• STAT+: Sanofi, Regeneron expand partnership after Dupixent success
  Sanofi and Regeneron have re-upped their collaboration pact, aiming to build on the blockbuster success of the drug Dupixent.
  stat · 17d ago